Feb 13 (Reuters) - Conduit Pharmaceuticals CDT.O:
CONDUIT PHARMACEUTICALS INC: PARTNERS WITH CHARLES RIVER IN CLINICALLY RELEVANT SYSTEMIC LUPUS ERYTHEMATOSUS MODEL
CONDUIT PHARMACEUTICALS: STUDY TO ACCELERATE DEVELOPMENT OF AZD1656 FOR AUTOIMMUNE DISORDERS, FOCUS ON SYSTEMIC LUPUS ERYTHEMATOSUS, LUPUS NEPHRITIS
Source text: ID:nGNX6dgWCT
Further company coverage: CDT.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.